



Petrovax is a company of novel biopharmaceutical practices with 30 years of successful experience.

The product portfolio includes original pharmaceutical products and vaccines, biotechnology drugs, branded generics and food supplements.

Petrovax is the holder of patents for molecules and pharmaceutical manufacturing technologies in Russia and abroad. Own R&D center for pre-clinical studies enables a full cycle of drug development.

Petrovax's modern manufacturing complex in the Moscow Region operates in full compliance with the EAEU and EU GMP standards. The synthesis of APIs, sterile and non-sterile pharmaceutical forms production is performed at the manufacturing complex. The annual production capacity is 160 million doses.

Company is one of the largest Russian exporters of original medicinal products and vaccines, which are supplied to EAEU and EU countries.

Petrovax is implementing international projects on the transfer of manufacturing technologies of high-tech pharmaceuticals in collaboration with leading pharmaceutical companies: Pfizer, Abbott, ISU ABXIS, and Adimmune.

The development strategy focuses on providing patients with in-demand vaccines and medicines for the prevention and treatment of socially significant conditions, such as infectious, oncological, and orphan diseases.

Petrovax has over 800 employees.

The company's vision: «Leading pharmaceutical innovations».

Our mission: «Expanding access to cutting-edge therapies».

Contact Us:

NPO Petrovax Pharm, LLC

123112, Moscow, Presnenskaya embankment, 12, Federation Tower (East), floor 38

Phone: +7 (495) 730-75-45

e-mail: info@petrovax.ru, www.petrovax.com